Verapamil is Less Effective than Triamcinolone for Prevention of Keloid Scar Recurrence After Excision in a Randomized Controlled Trial
| Autor: | Patricia L Danielsen, Suzanne Rea, Mitali Manzur, Hilary J. Wallace, Mansour A. Alghamdi, Thilanee U Gankande, Helena M. Viola, Andrew W. Stevenson, Fiona M. Wood, Livia C. Hool, Mark W. Fear |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male medicine.medical_specialty Triamcinolone acetonide Adolescent Vasodilator Agents Dermatology Injections Intralesional Triamcinolone Acetonide law.invention 030207 dermatology & venereal diseases 03 medical and health sciences Cicatrix 0302 clinical medicine Keloid Randomized controlled trial Double-Blind Method law Recurrence medicine Humans skin and connective tissue diseases Glucocorticoids Survival analysis business.industry Hazard ratio Antagonist General Medicine Middle Aged medicine.disease Interim analysis Surgery Treatment Outcome Verapamil 030220 oncology & carcinogenesis Female business medicine.drug |
| Zdroj: | Acta dermato-venereologica. 96(6) |
| ISSN: | 1651-2057 |
| Popis: | A double-blind randomized controlled trial with a paired split-scar design compared verapamil, an L-type Ca2+ channel antagonist, and triamcinolone for prevention of keloid recurrence after excision. Ca2+ channel blocking activity of verapamil in keloid cells was explored. One keloid was excised per subject and each wound half randomized to receive intralesional injections of triamcinolone (10 mg/ml) or verapamil (2.5 mg/ml) at monthly intervals (4 doses). Interim analysis was performed after 14 subjects were completed. Survival analysis demonstrated significantly higher keloid recurrence with verapamil compared to triamcinolone 12 months post-surgery (log-rank test, p = 0.01) and higher overall risk of recurrence with verapamil (hazard ratio 8.44, 95% CI 1.62-44.05). The study was terminated early according to the stopping guideline (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|